Dai Liang, Ooi Vee Voon, Zhou Wenjun, Ji Guang
Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Medicine (Baltimore). 2020 Jan;99(3):e18775. doi: 10.1097/MD.0000000000018775.
Non-alcoholic fatty liver disease (NAFLD) with abnormal transaminase were main targeted disorder in clinical intervention. Acupuncture embedding has been used as a modified acupuncture therapy in current management, while no comprehensive summarization has been established. Hence, we conducted a systematic review and meta-analysis to evaluate the effectiveness and safety of acupoint embedding alone or in combination for NAFLD with abnormal transaminase, and to provide potential regimen for further verification.
Seven English and Chinese databases were systematically researched from inception to February 28, 2019, including PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Chinese biomedical literature database (SinoMed), Chinese National Knowledge Infrastructure (CNKI), Chinese VIP information (VIP), and WanFang database. Academic dissertations were also searched as supplement. The searching terms included "nonalcoholic fatty liver disease," "acupoint embedding," "clinical trial," with their corresponding synonyms. Randomized controlled trials (RCTs) and quasi-RCTs involving acupoint embedding alone or in combination for adult patients with NAFLD with abnormal transaminase were included. The diagnosis of NAFLD should be confirmed by radiologic evidence. Two researchers independently completed predefined data sets extraction and quality assessment. STATA 15.0 was applied to estimate the combined effect presented as odds ratio or mean difference (MD) with a 95% confidence interval (CI). The primary outcome was the change of serum alanine aminotransferase (ALT).
A total of fifteen studies with 1349 patients were included. Meta-analysis reported that acupoint embedding alone or in combination was superior to conventional medications on ALT change (MD: 16.58, 95%CI: [10.42, 22.74], P < .001). The benefits were also demonstrated in other outcomes, including aspartate aminotransferase, triglyceride, and total cholesterol, total efficacy rate and radiological efficacy rate. The safety profile of acupoint embedding was satisfactory. BL18 (Ganshu) was the most frequently utilized acupoint.
To some extent, the systematic review supported the application of acupoint embedding in management of NAFLD, while further high-quality studies should be designed to evaluate the practical effect of acupoint embedding.
转氨酶异常的非酒精性脂肪性肝病(NAFLD)是临床干预的主要目标疾病。穴位埋线作为一种改良的针灸疗法已应用于当前的治疗中,但尚未有全面的总结。因此,我们进行了一项系统评价和荟萃分析,以评估单独或联合穴位埋线治疗转氨酶异常的NAFLD的有效性和安全性,并为进一步验证提供潜在方案。
系统检索了7个英文和中文数据库,时间跨度从建库至2019年2月28日,包括PubMed、Embase、Cochrane对照试验中心注册库(CENTRAL)、中国生物医学文献数据库(SinoMed)、中国知网(CNKI)、维普资讯(VIP)和万方数据库。还检索了学术论文作为补充。检索词包括“非酒精性脂肪性肝病”“穴位埋线”“临床试验”及其相应的同义词。纳入了单独或联合穴位埋线治疗成人转氨酶异常的NAFLD患者的随机对照试验(RCT)和半随机对照试验。NAFLD的诊断应通过影像学证据确认。两名研究人员独立完成预定义数据集的提取和质量评估。应用STATA 15.0估计合并效应,以比值比或均值差(MD)表示,并给出95%置信区间(CI)。主要结局是血清丙氨酸氨基转移酶(ALT)的变化。
共纳入15项研究,1349例患者。荟萃分析报告,单独或联合穴位埋线在ALT变化方面优于传统药物(MD:16.58,95%CI:[10.42,22.74],P <.001)。在其他结局中也显示出益处,包括天冬氨酸氨基转移酶、甘油三酯、总胆固醇、总有效率和影像学有效率。穴位埋线的安全性良好。肝俞(BL18)是最常使用的穴位。
本系统评价在一定程度上支持穴位埋线在NAFLD治疗中的应用,同时应设计进一步的高质量研究来评估穴位埋线的实际效果。